Breast Cancer Clinical Trial

Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy

Summary

Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients with inadequate response, if detected early. Investigators propose to develop a sodium breast MRI technique that will allow to assess the early metabolic response of breast cancer to NACT, occurring before late structural changes can be detected with standard MRI.

This study will scan 12 patients using 1H/23Na MRI at 7 T and DCE MRI with triple-negative breast cancer undergoing AC-T therapy (2 months of Adriamycin + Cyclophosphamide, then 3 months of Taxol): at baseline (pre-NACT); after the first AC cycle (2 weeks); after AC treatment (2 months); after complete NACT (5 months, pre-surgery).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women with no sign of breast cancer as controls
Non-pregnant and non-lactating
Ability to understand and willingness to sign a written consent

Exclusion Criteria:

Contra-indications to MRI (i.e., ferromagnetic prostheses, metallic surgical implants that are not compatible with an MRI machine, claustrophobia etc.)
Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient.
Pregnant or lactating women, women using hormonal treatment in the 6 months prior to the study.
Women with history of breast disease, previous breast surgery, or breast implants.
Patients with a currently active second malignancy other than non-melanoma skin cancers. Patients are not considered to have a currently active malignancy if they have completed therapy and are free of disease for 3 years.
Psychiatric illness or other conditions and circumstances which could prevent the patient from being compliant with the protocol.

Study is for people with:

Breast Cancer

Estimated Enrollment:

2

Study ID:

NCT03750240

Recruitment Status:

Terminated

Sponsor:

NYU Langone Health

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

NYU Langone Health
New York New York, 10016, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

2

Study ID:

NCT03750240

Recruitment Status:

Terminated

Sponsor:


NYU Langone Health

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider